Medicine
Spinosad 9 mg/mL topical suspension
Spinosad 9 mg/mL topical suspension is a generic prescription medicine for topical use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
Key facts
- Active ingredient (INN)
- Spinosad
- Brand
- Sold under the generic name
- Strength
- 9 mg/mL
- Dosage form
- Topical suspension
- Route
- Topical
- Packs
- 1 bottle
- Manufacturers
- Allegis PharmaceuticalsCipher PharmaceuticalsParaPRO
- Origin register
- US FDA, United States
- Storage
- Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 June 2014
- Identifiers
- RxCUI 1085816DailyMed set ID 16a95039-0df7-45d5-8b51-bbc81443fea3, 0d6e2507-3669-441e-b5ba-86087fd2955d, 8e87bd3b-db25-4e97-bf57-96c875f67ce1NDC 84635-570, 52246-570, 28595-570Application NDA022408
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, plastic in 1 carton / 120 mL in 1 bottle, plastic | 28595-570-04 | Allegis Pharmaceuticals | 25 June 2014 |
| 1 bottle, plastic in 1 carton / 120 mL in 1 bottle, plastic | 84635-570-04 | Cipher Pharmaceuticals | 19 January 2026 |
| 1 bottle, plastic in 1 carton / 120 mL in 1 bottle, plastic | 52246-570-04 | ParaPRO | 29 January 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 January 2011 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Spinosad 9 mg/mL topical suspension.
Clinical summary
Spinosad is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older, among other approved uses. It is available as topical suspension. MedsAcross supplies Spinosad for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SpinosadFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Natroba prescribing information (Cipher Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Spinosad 9 mg/mL topical suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.